3.4.22.B50	 In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2	equine arteritis virus	
3.4.22.B50	 In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2	equine arteritis virus Bucyrus	
3.4.22.B50	 Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis	Murine coronavirus	
3.4.22.B50	 Porcine epidemic diarrhea virus papain-like protease 2 can be noncompetitively inhibited by 6-thioguanine	porcine epidemic diarrhea virus	
3.4.22.B50	Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications	Human coronavirus NL63	
3.4.22.B50	Coronavirus papain-like endopeptidases	Alphacoronavirus	
3.4.22.B50	Deubiquitinase activity and regulation of antiviral innate immune responses by papain-like proteases of human coronavirus NL63	Human coronavirus NL63	
3.4.22.B50	Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells	equine arteritis virus	
3.4.22.B50	Enhancement of proteolytic activity of a thermostable papain-like protease by structure-based rational design	Tabernaemontana divaricata	
3.4.22.B50	Expression of murine coronavirus recombinant papain-like proteinase: efficient cleavage is dependent on the lengths of both the substrate and the proteinase polypeptide	Murine coronavirus	
3.4.22.B50	Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication	Human coronavirus 229E	
3.4.22.B50	Identification of mouse hepatitis virus papain-like proteinase 2 activity	Murine coronavirus	
3.4.22.B50	Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition	Alphacoronavirus	
3.4.22.B50	Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition	Alphacoronavirus SARS-CoV	
3.4.22.B50	PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway	Murine hepatitis virus	
3.4.22.B50	Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63	Human coronavirus NL63	
3.4.22.B50	Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme	Alphacoronavirus	
3.4.22.B50	Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme	Alphacoronavirus SARS-CoV	
3.4.22.B50	Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease	Severe acute respiratory syndrome-related coronavirus	
3.4.22.B50	Structural view and substrate specificity of papain-like protease from avian infectious bronchitis virus	infectious bronchitis virus	
3.4.22.B50	The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme	Alphacoronavirus	
3.4.22.B50	The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme	Alphacoronavirus SARS-CoV	
3.4.22.B50	The papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase	porcine epidemic diarrhea virus	
3.4.22.B50	The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity	Alphacoronavirus	
3.4.22.B50	The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity	Alphacoronavirus SARS-CoV	
3.4.22.B50	The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds	Severe acute respiratory syndrome-related coronavirus